Ignite Creation Date:
2024-05-06 @ 4:12 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04908813
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-15
First Post:
2021-05-21
Brief Title:
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
Sponsor:
Shanghai Henlius Biotech
Organization:
Shanghai Henlius Biotech
Organization Data
Organization:
Shanghai Henlius Biotech
Class:
INDUSTRY
Study ID:
HLX22-GC-201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Henlius Biotech
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None